Nux Vomica (Strychnos nux-vomica)

Nux vomica contains strychnine and brucine as primary alkaloids that affect the central nervous system by blocking glycine and GABA receptors. This Ayurvedic seed extract has been traditionally used for neurological conditions, though clinical evidence remains extremely limited.

Origin & History

Nux Vomica derives from the dried ripe seeds of the Strychnos nux-vomica L. tree (family Loganiaceae), an evergreen species native to Southeast Asia. The seeds are typically processed through traditional methods like decoction or compatibility with other herbs to reduce toxicity of the main alkaloids strychnine and brucine.

Historical & Cultural Context

In Traditional Chinese Medicine, Nux Vomica has been used for treating ischemic stroke, neurodisorders, arthritis, and rheumatism through its actions of dredging collaterals and relieving pain. Unani medicine traditionally uses the seeds (Azraqi) to elevate blood pressure, while Southeast Asian traditions employed it for various symptoms including indigestion and nausea.

Health Benefits

• May support recovery from spinal cord injury (based on one animal study, PMID: 32527244) - evidence quality: preliminary
• Traditional use for ischemic stroke management through multi-pathway mechanisms targeting serotonergic and calcium signaling - evidence quality: theoretical/traditional only
• Potential anti-inflammatory effects via PTGS2/COX-2 pathway modulation - evidence quality: in vitro only
• Historical application for arthritis and rheumatic pain relief - evidence quality: traditional use only
• Possible neuroprotective effects through multiple receptor targets including CHRNA7 and HTR3A - evidence quality: computational predictions only

How It Works

Strychnine, the primary alkaloid in nux vomica, acts as a competitive antagonist of glycine receptors in the spinal cord and brainstem. This blockade prevents inhibitory neurotransmission, leading to increased neuronal excitability. Brucine, the secondary alkaloid, has similar but weaker glycine receptor antagonist properties and may modulate calcium channels and serotonergic pathways.

Scientific Research

No human clinical trials, RCTs, or meta-analyses on Nux Vomica exist in the current research. Evidence is limited to animal models including a rat spinal cord injury study (PMID: 32527244) showing sensory/motor recovery, and toxicity studies in rats (n=36) demonstrating metabolic disruptions at 0.315-0.630 g/kg doses. Network pharmacology predictions suggest 14 active compounds targeting 59 genes relevant to ischemic stroke, but human validation is absent.

Clinical Summary

Clinical evidence for nux vomica is extremely limited and largely theoretical. One animal study (PMID: 32527244) suggested potential benefits for spinal cord injury recovery in rats, but no human clinical trials exist. Traditional Ayurvedic literature describes use for stroke management through multi-pathway mechanisms, but this lacks scientific validation. The evidence base consists primarily of preclinical research and traditional use reports rather than controlled human studies.

Nutritional Profile

{"macronutrients": {"protein": "Approximately 5-10% of dry weight", "fiber": "Approximately 10-15% of dry weight"}, "micronutrients": {"vitamins": {"Vitamin C": "Trace amounts"}, "minerals": {"Calcium": "Approximately 200-250 mg per 100g", "Magnesium": "Approximately 100-150 mg per 100g", "Iron": "Approximately 5-10 mg per 100g"}}, "bioactive_compounds": {"Strychnine": "Approximately 1-2% of dry weight", "Brucine": "Approximately 0.5-1% of dry weight"}, "bioavailability_notes": "Strychnine and brucine are highly toxic alkaloids with limited therapeutic window. Nutrient bioavailability may vary based on preparation and individual health conditions."}

Preparation & Dosage

No clinically studied human dosage ranges are available. Animal toxicity studies used 0.315-0.630 g/kg body weight orally in rats (decoction form), which caused organ damage. Traditional use emphasizes strict control of strychnine/brucine content via processing, but no standardized extract dosages are specified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not recommended due to toxicity concerns

Safety & Interactions

Nux vomica is extremely toxic due to strychnine content, with therapeutic doses dangerously close to lethal amounts. Strychnine poisoning causes violent muscle spasms, convulsions, and respiratory failure. It may interact with medications affecting GABA or glycine neurotransmission, including benzodiazepines and muscle relaxants. Pregnant and breastfeeding women should absolutely avoid nux vomica due to severe toxicity risks to both mother and child.